Longtime Zymeworks CEO, co-founder Tehrani hits the exit in favor of serial biotech entrepreneur
After a down year, biopharma writ large is looking for a breath of fresh air — and now the winds of change have hit oncology bispecifics player Zymeworks.
Ali Tehrani, a co-founder of Zymeworks who has been the biotech’s CEO since 2003, has resigned from his position and will be replaced by Ken Galbraith, a serial biotech entrepreneur and former board member, the company said Wednesday.
Tehrani will take on an advisory role with the company once his tenure formally ends Feb. 1 to help aid in the transition for Galbraith’s leadership turn. Meanwhile, board chair Lota Zoth will be moved into an independent director role in conjunction with the shakeup.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters